Phase I, Open-label Trial to Evaluate the Safety and Immunogenicity of INO-5150 Alone or in Combination With INO-9012 in Men With Biochemically Relapsed (PSA) Prostate Cancer

Trial Profile

Phase I, Open-label Trial to Evaluate the Safety and Immunogenicity of INO-5150 Alone or in Combination With INO-9012 in Men With Biochemically Relapsed (PSA) Prostate Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs INO 5150 (Primary) ; INO 9012
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Inovio Pharmaceuticals
  • Most Recent Events

    • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
    • 11 Sep 2017 Results published in an Inovio Pharmaceuticals media release.
    • 11 Sep 2017 According to an Inovio Pharmaceuticals media release, results were presented as a poster discussion at the 2017 European Society of Medical Oncology (ESMO) meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top